PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Trimbow NEXThaler (formoterol/beclometasone/glycop - Chronic Obstructive Pulmonary Disease (COPD)

PAD Profile : Trimbow NEXThaler (formoterol/beclometasone/glycop - Chronic Obstructive Pulmonary Disease (COPD)

Keywords :
Chronic Obstructive Pulmonary Disease, LABA beta agonist, long acting, ICS, antimuscarinic, triple therapy
Brand Names Include :
Trimbow NEXThaler

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
COPD Primary Care Medicines Management Guidelines - updated Jun 23
01 June 2026
Evidence Review
Trimbow Nexthaler Formulary extension for COPD - Jun 23

Committee Recommendations

Date
Committee Name
Narrative
07 June 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee has agreed Trimbow® NEXThaler® as an option where triple therapy is indicated in the treatment of COPD. See COPD Guidelines for more information.

The locally preferred triple-therapy devices for COPD are:

Low carbon:
Trimbow NEXThaler (dry powder)
Trelegy Ellipta (dry powder)

Alternative devices:
Trimbow (pMDI). To be used with a spacer.

Prescribe devices by brand.

Associated BNF Codes

03. Respiratory System
03.01.01. Adrenoceptor agonists
03.01.02. Antimuscarinic bronchodilators
03.02.00. Corticosteroids (respiratory)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More